New Delhi, Nov 8 (PTI) Biocon Biologics on Wednesday said it has inked a pact with Eris Lifesciences for the sale of its dermatology and nephrology branded formulations business units in India for Rs 366 crore.

The companies have inked definitive agreements for the same.

Also Read | Uttarakhand Day 2023 Date: Know the History & Significance of Uttarakhand Sthapna Diwas That Marks the State Foundation Day.

The transaction is a slump sale that will enable a seamless transfer of the product brands and employees associated with these businesses, Biocon Biologics, a unit of Biocon Ltd, said in a statement.

The total transaction value of the divestment is Rs 366 crore, inclusive of working capital conveyed as part of the deal, it added.

Also Read | CAT 2023 Exam Admit Card Out at iimcat.ac.in: Hall Ticket for Common Eligibility Test Examination Released, Know Steps To Download.

Post-deal close, over 120 employees of the two business units are expected to transition to Eris, ensuring continuity for both employees and patients, Biocon Biologics said.

The divestiture is expected to close by the end of November 2023, subject to customary closing conditions, it added.

The divestment of the non-core branded formulations business units in India is in line with the company's strategy to sharpen focus on core therapy areas as a fully integrated biosimilars company, it said.

"This divesture of non-core assets allows Biocon Biologics to unlock value within our branded formulations portfolio in India and sharpen focus on our core therapy areas like diabetes, oncology and immunology," Biocon Biologics CEO and Managing Director Shreehas Tambe said.

The company believes that Eris Lifesciences is well positioned to build further on the dermatology and nephrology franchise in India, he added.

Eris Lifesciences Chairman & Managing Director Amit Bakshi said that the company has successfully demonstrated its ability to turn around and create value in acquired businesses.

"The acquisition of Biocon Biologics' Nephrology and Dermatology Branded Formulations businesses in India is in line with our strategic goals as well as our capital allocation framework," he added.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)